Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase I/Ib clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; Foundation Medicine, Inc. for the provision of prospective genomic profiling of lunresertib alone or in combinations in genomically-defined patient populations; cooperative research and development agreement with US National Cancer Institute to advance the development of Camonsertib; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada. more
Time Frame | RPTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -43.81% | -2.27% | -0.57% |
1-Month Return | -45.71% | -3.96% | 1.21% |
3-Month Return | -49.86% | -9.7% | 7.57% |
6-Month Return | -54.85% | -3.37% | 11.45% |
1-Year Return | -73.02% | 3.71% | 28.48% |
3-Year Return | -91.28% | 3.8% | 29.52% |
5-Year Return | -94.25% | 39.78% | 90.66% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 135.00K | 7.60M | 131.83M | 51.13M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.1,"profit":true},{"date":"2021-12-31","value":5.77,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":38.79,"profit":true}] |
Cost of Revenue | 968.00K | 1.79M | 3.34M | 4.18M | 131.20M | [{"date":"2019-12-31","value":0.74,"profit":true},{"date":"2020-12-31","value":1.36,"profit":true},{"date":"2021-12-31","value":2.55,"profit":true},{"date":"2022-12-31","value":3.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (968.00K) | (1.65M) | 4.26M | 127.65M | (80.07M) | [{"date":"2019-12-31","value":-0.76,"profit":false},{"date":"2020-12-31","value":-1.29,"profit":false},{"date":"2021-12-31","value":3.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-62.73,"profit":false}] |
Gross Margin | - | (1223.70%) | 56.00% | 96.83% | (156.59%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1263.81,"profit":false},{"date":"2021-12-31","value":57.84,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-161.72,"profit":false}] |
Operating Expenses | 26.38M | 54.44M | 116.26M | 151.63M | 167.36M | [{"date":"2019-12-31","value":15.76,"profit":true},{"date":"2020-12-31","value":32.53,"profit":true},{"date":"2021-12-31","value":69.47,"profit":true},{"date":"2022-12-31","value":90.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (26.38M) | (54.30M) | (108.66M) | (19.80M) | (116.22M) | [{"date":"2019-12-31","value":-2637700000,"profit":false},{"date":"2020-12-31","value":-5430200000,"profit":false},{"date":"2021-12-31","value":-10866000000,"profit":false},{"date":"2022-12-31","value":-1979600000,"profit":false},{"date":"2023-12-31","value":-11622400000,"profit":false}] |
Total Non-Operating Income/Expense | - | (200.00K) | 333.00K | 11.53M | 26.20M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-0.76,"profit":false},{"date":"2021-12-31","value":1.27,"profit":true},{"date":"2022-12-31","value":43.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (27.02M) | (54.74M) | (108.59M) | (13.90M) | (103.18M) | [{"date":"2019-12-31","value":-2702100000,"profit":false},{"date":"2020-12-31","value":-5474200000,"profit":false},{"date":"2021-12-31","value":-10858600000,"profit":false},{"date":"2022-12-31","value":-1390000000,"profit":false},{"date":"2023-12-31","value":-10317900000,"profit":false}] |
Income Taxes | 195.00K | (1.32M) | (1.68M) | 15.15M | (9.38M) | [{"date":"2019-12-31","value":1.29,"profit":true},{"date":"2020-12-31","value":-8.75,"profit":false},{"date":"2021-12-31","value":-11.08,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-61.95,"profit":false}] |
Income After Taxes | - | (53.42M) | (106.91M) | (29.05M) | (93.80M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-5341700000,"profit":false},{"date":"2021-12-31","value":-10690800000,"profit":false},{"date":"2022-12-31","value":-2904700000,"profit":false},{"date":"2023-12-31","value":-9379600000,"profit":false}] |
Income From Continuous Operations | (27.22M) | (53.42M) | (106.91M) | (29.05M) | (97.42M) | [{"date":"2019-12-31","value":-2721600000,"profit":false},{"date":"2020-12-31","value":-5341700000,"profit":false},{"date":"2021-12-31","value":-10690800000,"profit":false},{"date":"2022-12-31","value":-2904700000,"profit":false},{"date":"2023-12-31","value":-9742400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (27.22M) | (53.42M) | (106.91M) | (29.05M) | (93.80M) | [{"date":"2019-12-31","value":-2721600000,"profit":false},{"date":"2020-12-31","value":-5341700000,"profit":false},{"date":"2021-12-31","value":-10690800000,"profit":false},{"date":"2022-12-31","value":-2904700000,"profit":false},{"date":"2023-12-31","value":-9379600000,"profit":false}] |
EPS (Diluted) | - | (4.09) | (2.82) | (0.78) | (2.23) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-409,"profit":false},{"date":"2021-12-31","value":-282,"profit":false},{"date":"2022-12-31","value":-78,"profit":false},{"date":"2023-12-31","value":-223,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RPTX | |
---|---|
Cash Ratio | 5.77 |
Current Ratio | 6.45 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RPTX | |
---|---|
ROA (LTM) | -23.39% |
ROE (LTM) | -41.17% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RPTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.15 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.85 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RPTX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 2.54 |
P/B | 0.87 |
Price/FCF | NM |
EV/R | 0.02 |
EV/Ebitda | 0.58 |
Repare Therapeutics Inc (RPTX) share price today is $1.77
Yes, Indians can buy shares of Repare Therapeutics Inc (RPTX) on Vested. To buy Repare Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RPTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Repare Therapeutics Inc (RPTX) via the Vested app. You can start investing in Repare Therapeutics Inc (RPTX) with a minimum investment of $1.
You can invest in shares of Repare Therapeutics Inc (RPTX) via Vested in three simple steps:
The 52-week high price of Repare Therapeutics Inc (RPTX) is $8.49. The 52-week low price of Repare Therapeutics Inc (RPTX) is $2.71.
The price-to-earnings (P/E) ratio of Repare Therapeutics Inc (RPTX) is
The price-to-book (P/B) ratio of Repare Therapeutics Inc (RPTX) is 0.87
The dividend yield of Repare Therapeutics Inc (RPTX) is 0.00%
The market capitalization of Repare Therapeutics Inc (RPTX) is $168.77M
The stock symbol (or ticker) of Repare Therapeutics Inc is RPTX